^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Aromatase inhibitor

    Related drugs:
    3d
    Clinical Study of Jinfeng Pill and Letrozole Combination Therapy for PCOS-Related Infertility (ChiCTR2600117547)
    P=N/A, N=264, Not yet recruiting, Shanghai First Maternity and Infant Hospital; Shanghai First Maternity and Infant Hospital
    New trial
    |
    letrozole
    3d
    Randomized Controlled Trial Comparing Letrozole-Induced Ovulation Versus Natural Cycle Single-Blastocyst Frozen Embryo Transfer on Pregnancy Outcomes in Normally Ovulatory Women (ChiCTR2500114189)
    P=N/A, N=352, Recruiting, Beijing Chao-Yang Hospital, Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
    New trial
    |
    letrozole
    3d
    The Effect of Estrogen Supplementation on Clinical Pregnancy Rate in Letrozole-Induced Ovulation: A Prospective Randomized Controlled Trial (ChiCTR2500115444)
    P4, N=420, Not yet recruiting, Dongguan People's Hospital; Dongguan People's Hospital
    New P4 trial
    |
    letrozole
    6d
    APPOSE: Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis (clinicaltrials.gov)
    P2, N=60, Completed, University of California, San Francisco | Active, not recruiting --> Completed
    Trial completion
    |
    letrozole
    7d
    Late Cervical Recurrence of Invasive Lobular Carcinoma Ten Years After Primary Breast Cancer: A Case Report and Review of the Literature. (PubMed, Healthcare (Basel))
    The patient began systemic therapy with ribociclib plus letrozole, achieving radiologic improvement of the cervical lesion and abdominal disease. This case highlights the ability of ILC to recur after long latency and to metastasize to unusual gynecologic sites such as the cervix. We also review the literature on cervical recurrence from lobular carcinoma to emphasize the importance of gynecologic surveillance in breast cancer survivors and to identify areas that require further investigation.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3)
    |
    ER positive • HER-2 negative • BRCA mutation • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • letrozole
    7d
    Sapu003 in Advanced mTOR-sensitive Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, SAPU NANO (US) LLC
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • exemestane
    7d
    Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. (PubMed, Nat Commun)
    Additionally, a 33-gene signature that predicted neoadjuvant Ki67 response to ANA/PAL was prognostic in a metastatic validation cohort. These findings underscore dysregulated oncogenic pathways as potential resistance mechanisms and biomarkers of response to CDK4/6i.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Ibrance (palbociclib) • anastrozole
    7d
    Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)
    Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 negative • HER-2 expression
    |
    tamoxifen • letrozole • anastrozole
    8d
    NCI-2021-12428: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (clinicaltrials.gov)
    P4, N=68, Recruiting, University of Washington | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    letrozole
    8d
    Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial. (PubMed, Clin Cancer Res)
    Pretreatment and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR+/HER2- ABC treated with ribociclib/letrozole. Early ctDNA dynamic appeared a promising surrogate biomarker for treatment. Further studies are warranted to validate their clinical utility.
    Journal • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDK4 (Cyclin-dependent kinase 4)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Kisqali (ribociclib) • letrozole
    11d
    ALTERNATE: Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery (clinicaltrials.gov)
    P3, N=1473, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Aug 2025 --> Apr 2027 | Trial primary completion date: Aug 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    fulvestrant • anastrozole
    12d
    Case Report: Metastasis of low-grade endometrial stromal sarcoma to the inferior vena cava and right atrium: a case of successful one-stage surgical resection with favorable early outcome. (PubMed, Front Radiol)
    The patient recovered uneventfully with no residual disease on follow-up and commenced adjuvant letrozole therapy. This case highlights the necessity of multimodal imaging for accurate staging of complex vascular involvement and demonstrates that aggressive one-stage surgical management is a viable strategy to achieve locoregional control and favorable early outcomes for advanced LGESS with cardiac metastasis.
    Journal
    |
    MME (Membrane Metalloendopeptidase)
    |
    letrozole